clinical trials

Chromadex Corp (NASDAQ: CDXC) shares jumped 111% in the regular and after-hours sessions today. What Happened: The price movement on Thursday was accompanied by intense trading with volumes of 116.67 million. The average volume for ChromaDex shares is 523,511. While there were no immediate triggers...

China's Sinopharm Group (OTC: SHTDY) said Wednesday its COVID-19 vaccine candidate BBIBP-CorV — developed in partnership with Beijing Biological Products Institute Co. Ltd — shows 79.34% efficacy, Reuters reports. What Happened: Beijing Biological...

AstraZeneca Plc (NYSE: AZN) and Oxford University’s COVID-19 vaccine prevented 70% of the inoculated trial participants from developing COVID-19, early analysis of trial data indicates. What Happened: The results were based on data gathered from two different dosing regimens. One dosing...

Johnson & Johnson (NYSE: JNJ) has started the two-dose Phase 3 trial of its experimental COVID-19 vaccine, dubbed "ENSEMBLE 2," the pharmaceutical company announced Sunday. What Happened: Johnson & Johnson aims to administer its experimental COVID-19 vaccine to 30,000...

Brazilian health regulator has decided to halt clinical trials of a frontrunning Chinese vaccine following a “severe adverse event” observed in a participant, Bloomberg reported Monday. CoronaVac, a vaccine candidate developed through joint efforts by Chinese biopharma...

Biopharmaceutical company GW Pharmaceuticals plc (NASDAQ: GWPH) revealed Tuesday that its revenue for the third quarter hit $137.1 million, up by 51% year-over-year. For the first nine months of this fiscal year, total revenue amounted to $378.6 million versus $202.3 million for the...

The U.S. Food and Drug Administration (FDA) has completed a review of adverse events observed in participants of AstraZeneca Plc’s (NASDAQ: AZN) COVID-19 vaccine clinical trial, according to Reuters. What Happened: The U.S. trial of the British company's vaccine candidate...

Johnson & Johnson’s (NYSE: JNJ) COVID-19 vaccine trial has been paused over a participant developing an unexplained illness, Stat reported late Monday. The company later confirmed the move in a statement. What Happened: The pharmaceutical company reportedly told the researchers conducting...

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) CEO Leonard Schleifer in a televised interview suggested that more clinical testing was needed to measure the company's antibody cocktail's effectiveness against COVID-19, in contrast to President Donald Trump who earlier claimed...

Novavax, Inc (NASDAQ: NVAX) said Thursday it was launching a large-scale diverse Phase 3 study of its COVID-19 vaccine in the United Kingdom — causing a more than 7% spike in the company’s shares after the closing bell. What Happened: The study will enroll up to 100,000 individuals...

Sinovac Biotech has plans to expand the clinical trial of its COVID-19 vaccine trial to children and adolescents later this month. What Happened: The Chinese vaccine maker hopes to carry out the study on 552 healthy participants ranging between the ages of three and 17, according to information the...

AstraZeneca plc (NYSE: AZN) COVID-19 vaccine clinical trial is set to resume in India after local partner Serum Institute of India received the go-ahead from Indian regulators, Reuters reported Wednesday. What Happened: The Drugs Controller General of India has approved the trial of the...

Pfizer Inc (NYSE: PFE) on Tuesday said only mild-to-moderate side effects were observed in volunteers administered with its COVID-19 vaccine in late-stage human trials. What Happened: The ongoing Phase 3 trials were carried out in such a way that 50% of the participants received its...

Pfizer Inc (NYSE: PFE) and its German partner BioNTech SE (NASDAQ: BNTX) said Saturday they are seeking the United States Food and Drug Administration approval to expand the late-stage clinical trial of their COVID-19 vaccine, by significantly upping the number of participants and increasing their...

AstraZeneca Plc’s (NYSE: AZN) COVID-19 vaccine trial halt is an indicator that vaccine development is “not always a fast and a straight road,” according to the World Health Organization Chief Scientist Dr. Soumya Swaminathan. What Happened: The WHO official said that the vaccine...